Pulse Biosciences (PLSE)

Executive Summary

Pulse Biosciences is a medical device company commercializing its proprietary nPulse™ technology, a novel non-thermal ablation platform applied across dermatology, oncology, and cardiology. The company's flagship CellFX® system has received FDA clearance for the treatment of seborrheic keratosis and is expanding into benign thyroid nodules and atrial fibrillation. With a strong intellectual property portfolio and a growing body of clinical evidence, Pulse Biosciences aims to disrupt the soft tissue ablation market by offering a precise, cell-selective modality with minimal collateral damage. The company's strategic focus on high-value indications and its recent progress in cardiac ablation position it for significant growth, though commercialization challenges and competitive pressures remain. Financially, the company has a public float and a market capitalization around $2 billion.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for atrial fibrillation ablation60% success
• Q3 2026Quarterly commercial revenue update from CellFX system70% success
• Q4 2026Publication of clinical data for benign thyroid nodule ablation50% success